Artivion Correlations
AORT Stock | USD 28.41 0.14 0.50% |
The current 90-days correlation between Artivion and Nutex Health is 0.08 (i.e., Significant diversification). The correlation of Artivion is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Artivion Correlation With Market
Poor diversification
The correlation between Artivion and DJI is 0.61 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Artivion and DJI in the same portfolio, assuming nothing else is changed.
Artivion |
Moving together with Artivion Stock
0.64 | VMD | Viemed Healthcare | PairCorr |
0.7 | ITGR | Integer Holdings Corp | PairCorr |
0.64 | NXGL | Nexgel Inc | PairCorr |
0.63 | OMIC | Singular Genomics Systems | PairCorr |
0.67 | CRVL | CorVel Corp | PairCorr |
0.65 | EWTX | Edgewise Therapeutics | PairCorr |
0.77 | EXEL | Exelixis | PairCorr |
0.72 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
Moving against Artivion Stock
0.63 | EVH | Evolent Health | PairCorr |
0.53 | AGL | agilon health Buyout Trend | PairCorr |
0.53 | PHG | Koninklijke Philips | PairCorr |
0.49 | AMN | AMN Healthcare Services | PairCorr |
0.47 | FORA | Forian Inc | PairCorr |
0.63 | ME | 23Andme Holding | PairCorr |
0.63 | DOMH | Dominari Holdings | PairCorr |
0.5 | VALN | Valneva SE ADR | PairCorr |
0.38 | VCNX | Vaccinex | PairCorr |
0.72 | HLN | Haleon plc | PairCorr |
0.69 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.65 | PFE | Pfizer Inc Aggressive Push | PairCorr |
0.64 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
0.61 | LLY | Eli Lilly | PairCorr |
0.45 | EXAS | EXACT Sciences | PairCorr |
0.35 | TIL | Instil Bio | PairCorr |
Related Correlations Analysis
0.22 | 0.41 | -0.46 | 0.48 | EUDA | ||
0.22 | 0.61 | -0.48 | -0.09 | NUTX | ||
0.41 | 0.61 | -0.62 | -0.05 | HCTI | ||
-0.46 | -0.48 | -0.62 | 0.14 | MGRX | ||
0.48 | -0.09 | -0.05 | 0.14 | ACON | ||
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Artivion Stock performing well and Artivion Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Artivion's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
EUDA | 4.66 | 0.05 | 0.00 | 0.21 | 6.79 | 9.70 | 26.33 | |||
NUTX | 5.51 | 0.76 | 0.14 | 0.60 | 5.37 | 11.28 | 47.75 | |||
HCTI | 7.89 | 1.80 | 0.16 | (8.42) | 8.74 | 10.34 | 131.09 | |||
MGRX | 4.35 | (0.53) | 0.00 | (3.42) | 0.00 | 7.29 | 37.65 | |||
ACON | 4.31 | (0.51) | 0.00 | (0.10) | 0.00 | 11.11 | 35.83 |
Artivion Corporate Management
Daniel Bevevino | Independent Director | Profile | |
Jean Holloway | Senior Vice President Chief Compliance Officer, General Counsel, Secretary | Profile | |
Jon Salveson | Independent Director | Profile | |
Andrew Green | Vice President - Regulatory Affairs | Profile | |
Thomas Ackerman | Independent Director | Profile | |
Rochelle Maney | Vice President - Global Quality Assurance | Profile |